Advertisement

Treater to Target: A Urologist’s Personal Experience with Prostate Cancer

  • Paul F. Schellhammer
Chapter

Abstract

A urologist’s personal experience with multiple surgical, hormonal, and radio/immunotherapeutic options for the treatment of advancing prostate cancer.

Keywords

Biochemical failure Stereotactic radiation Immunotherapy Clinical trials 

References

  1. 1.
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289–94.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Bjork T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472–9.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832–40.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–62.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Wilt TJ, Shamliyan T, Taylor B, MacDonald R, Tacklind J, Rutks I, et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative effectiveness review no. 13. (Prepared by Minnesota Evidence-based Practice Center under Contract No. 290-02-00009.). Agency for Healthcare Research and Quality: Rockville, MD; 2008.Google Scholar
  9. 9.
    Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–9.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Wibowo E, Schellhammer PF, Montie JE, Lange PH, Goldenberg SL. Should i get a PSA test?—The question is not that simple. Trends in Urology & Men’s Health. 2015; 31–4.Google Scholar
  12. 12.
    Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369:603–10.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, et al. Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study. Urol. 2014;84:393–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Schild SE, Wong WW, Grado GL, Halyard MY, Novicki DE, Swanson TSK, et al. The results of radical retropubic prostatectomy and adjuvant therapy for pathologic stage c prostate cancer. Int J Radiat Oncol Biol Phys. 1996;34:535–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein ER, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–41.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007;69:54–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Shipley WU. NRG oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. Abstract #3, 2016 genitourinary cancers symposium, ASCO meeting, January 7-9, 2016, San Francisco, CA.Google Scholar
  18. 18.
    Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSure. J Urol. 2004;171:215–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Lightner DJ, Lange PH, Reddy PK, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 1990;144:921–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001;166:111–5.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–9.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othee BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25:3281–7.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15:677–83.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    James ND. Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: survival results from STAMPEDE (NCT00268476). Abstract #162, 2016 Genitourinary cancers symposium, ASCO meeting, January 7-9, 2016, San Francisco, CA.Google Scholar
  26. 26.
    Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973–8.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Steensma DP. The ordinary miracle of cancer clinical trials. J Clin Oncol. 2009;27:1737–9.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Hussain M, Tangen CM, Higano C, Schellhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984–90.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997;80:1755–9.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003;21:99–105.CrossRefPubMedGoogle Scholar
  32. 32.
    Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer—forward to the past? J Urol. 2003;169:1735–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165–70.Google Scholar
  34. 34.
    Finkelstein JS, Lee H, Burnett-Bowie SM, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:1011–22.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Schellhammer PF. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:2456.PubMedGoogle Scholar
  36. 36.
    Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol. 2011;185:17–23.CrossRefPubMedGoogle Scholar
  37. 37.
    Wassersug RJ, Walker LM, Robinson JW. Androgen deprivation therapy, an essential guide for prostate cancer patients and their loved ones. New York: Demos Medical Publishing, LLC; 2014.Google Scholar
  38. 38.
    Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.CrossRefPubMedGoogle Scholar
  39. 39.
    Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–9.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate. 2008;68:1319–29.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2013;2:1–6.CrossRefGoogle Scholar
  45. 45.
    Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Muacevic A, Olivier K, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naïve recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.CrossRefPubMedCentralPubMedGoogle Scholar
  48. 48.
    Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Soto AM, Sonnenschein C. The two faces of janus: sex steroids as mediators of both cell proliferation and cell death. J Nat Cancer Inst. 2001;93:1673–5.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Paul F. Schellhammer
    • 1
  1. 1.Department of UrologyEastern Virginia Medical School, Urology of VirginiaVirginia BeachUSA

Personalised recommendations